Evidence map›Paper›PMID 19017976›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2008

TREM-2 mediated signaling induces antigen uptake and retention in mature myeloid dendritic cells.

Suresh Radhakrishnan, Laura N Arneson, Jadee L Upshaw, Charles L Howe, Sara J Felts, Marco Colonna, Paul J Leibson, Moses Rodriguez, Larry R Pease

RetractedOpen access · bronzeAbstract readRetracted Publication
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Suresh RadhakrishnanDepartment of Immunology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Laura N Arneson
Jadee L Upshaw
Charles L Howe
Sara J Felts
Marco Colonna
Paul J Leibson
Moses Rodriguez
Larry R Pease
Mayo Clinic · USWashington University in St. Louis · US

Funding

Promoting Tumor Immunity by Cross-Linking B7-DCR01CA104996 · NCI · MAYO CLINIC ROCHESTER · PI PEASE, LARRY R · 2004 to 2013
$2.1M
Blocking airway inflammation with B7-DC cross-linking AbR01HL077296 · NHLBI · MAYO CLINIC ROCHESTER · PI PEASE, LARRY R · 2006 to 2009
$1.5M
Potentiating DC Function through B7-DCR01CA096859 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI PEASE, LARRY R · 2003 to 2005
$767k
NCI NIH HHS R01 CA096859NCI NIH HHS R01 CA104996NCI NIH HHS R01 CA104996-4NCI NIH HHS R01 CA96859NHLBI NIH HHS R01 HL077296NHLBI NIH HHS R01 HL077296-3
6 · The paper itself

Abstract

Myeloid dendritic cells (mDC) activated with a B7-DC-specific cross-linking IgM Ab (B7-DC XAb) take up and retain Ag and interact with T cell compartments to affect a number of biologic changes that together cause strong antitumor responses and blockade of inflammatory airway disease in animal models. The molecular events mediating the initial responses in mDC remain unclear. In this study we show that B7-DC XAb caused rapid phosphorylation of the adaptor protein DAP12 and intracellular kinases Syk and phospholipase C-gamma1. Pretreatment of mDC with the Syk inhibitor piceatannol blocked B7-DC XAb-induced Ag uptake with a concomitant loss of tumor protection in mice. Vaccination with tumor lysate-pulsed wild-type B7-DC XAb-activated mDC, but not TREM-2 knockout XAb-activated mDC, protected mice from lethal melanoma challenge. Multimolecular caps appeared within minutes of B7-DC XAb binding to either human or mouse mDC, and FRET analysis showed that class II, CD80, CD86, and TREM-2 are recruited in tight association on the cell surface. When TREM-2 expression was reduced in wild-type mDC using short hairpin RNA or by using mDC from TREM-2 knockout mice, in vitro DC failed to take up Ag after B7-DC XAb stimulation. These results directly link TREM-2 signaling with one change in the mDC phenotype that occurs in response to this unique Ab. The parallel signaling events observed in both human and mouse mDC support the hypothesis that B7-DC cross-linking may be useful as a therapeutic immune modulator in human patients.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntibodiesAntigensB7-1 AntigenB7-2 AntigenDendritic CellsGene Expression RegulationHistocompatibility Antigens Class IIHumansImmunologic CappingInflammationIntracellular Signaling Peptides and ProteinsMelanomaMembrane GlycoproteinsMembrane Proteins3,3',4,5'-tetrahydroxystilbeneAdaptor Proteins, Signal TransducingAntibodiesAntigensB7-1 AntigenB7-2 AntigenCD86 protein, humanCd86 protein, mouseHistocompatibility Antigens Class IIIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsMembrane ProteinsPhospholipase C gammaProtein-Tyrosine KinasesReceptors, ImmunologicStilbenesSyk KinaseSYK protein, humanSyk protein, mouseTREM2 protein, humanTrem2 protein, mouseTYROBP protein, humanTyrobp protein, mouse

Identifiers

PMID19017976
PMCPMC2606976
OpenAlexW2113283378

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.